Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative oral (Z)-endoxifen for estrogen receptor-positive early breast cancer
ACTRN12618001561279Phase 2Terminated
- Sponsor
- Atossa Therapeutics
- Start
- Oct 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of z-endoxifen in breast cancer, sponsored by Atossa Therapeutics. Primary endpoint: Change in Ki-67 expression. Started Oct 2018; status: terminated.
02
Drugs
z-endoxifen
03
Conditions
breast cancer
Beyond the preview
Go deeper on ACTRN12618001561279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618001561279.